Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Sep 03, 2023 12:23am
167 Views
Post# 35617836

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Flexible design

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Flexible design I was thinking the same thing about going private.  I think we could do a better job running this company. I own more shares than most of the board members.  I know many of you on this chat board do as well.  I've been involved in financing requests larger than the Marathon deal, which is why I still cannot believe they violated two covenants in such a short amount of time.  I've helped raise capital, albeit not in this space, but the communication skills of this company will not lend itself to further investment unless there are MAJOR changes.  I'm extrememly disappointed they haven't managed their finances better.  I cannot believe they haven't further shrunk the board and reduced executive salaries or at least changed the compensation structure.  They waited too long to cut expenses and even longer to communicate it.  The financial explanations are embarassing to say the least.  It's like a novice analyst comparing year-over-year numbers without any real guidance other than top line revenue, which we've seen not only misses but changes.  While maybe not a traditional approach, they need to separate the legacy drugs into it's own class so that investors can see exactly how profitable that is and what it would mean in terms of share value.  

At this point, these guys have been such a colossal failure, I'd love to entertain putting a group together to go private.  Or facilitate a sale to a more capable company in an all stock transaction valuing THTX at $15/share.
<< Previous
Bullboard Posts
Next >>